Histamine Receptors as Drug Targets

A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Pharmacology".

Deadline for manuscript submissions: closed (30 June 2023) | Viewed by 368

Special Issue Editor

Faculty of Chemistry, Biological and Chemical Research Centre, University of Warsaw, Warsaw, Poland
Interests: GPCRs; membrane proteins; molecular dynamics; molecular modeling; molecular docking; drug design; inflammation; neurodegenerative diseases
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Histamine receptors, H(1-4)R, belong to the Rhodopsin-like subfamily of G-protein-coupled receptors. Histamine not only modulates the immune response and inflammation but also acts as a neurotransmitter in the central nervous system. The histaminergic system modulates different processes including wakefulness, appetite regulation, cognition, learning, and memory. The neuronal histaminergic system is involved in many physiological functions and is severely affected in neuropsychiatric disorders such as Parkinson's and Alzheimer's disease, as well as in schizophrenia, sleep disorders, drug dependence, Tourette's syndrome, autism, and other brain disorders. The histamine receptors have also been found to be involved in cancer development, growth, and metastasis. Histamine receptors are targeted in the treatment of neuropathic pain, and also as a therapeutic approach for heart failure. The expression of these receptors on different cell types is strictly regulated, and the diverse effects of histamine are due to differential expression of four histamine receptors and their distinct intracellular signaling. This Special Issue aims to highlight the latest discoveries in the histamine receptor field, as well as being open to novel discoveries in basic research and clinical findings or disease models that indicate regulation by histamine. On the molecular level, not only is drug-binding research welcomed but also investigations on interactions with the effector proteins, allosteric effects, and signal transduction including bias signaling.

Prof. Dr. Sławomir Filipek
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • histamine receptors
  • allergy
  • inflammation
  • autoimmune disorders
  • neuropathic pain
  • cancer
  • drug design
  • molecular modeling
  • allostery
  • signal transduction

Published Papers

There is no accepted submissions to this special issue at this moment.
Back to TopTop